Pharmaceutical

China’s NMPA approves Henlius’ oesophageal cancer therapy

China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).

Sep 25, 2023 - 20:00
China’s NMPA approves Henlius’ oesophageal cancer therapy
China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).
Read the original article

Tags:

Previous Article

Novartis eyes first-line status for its radionucleotide therapy Lutathera

Next Article

Valneva receives JE vaccine supply contract from US DoD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys

STAT+: Why Novartis is going to walk away from its acqu...

Feb 7, 2024

STAT+: Carl June unveils a plan for a ‘universal CAR-T’

STAT+: Carl June unveils a plan for a ‘universal CAR-T’

Sep 2, 2023

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda co...

May 29, 2024